London | Fast-growing Telix Pharmaceuticals has opened a $21 million nuclear medicine facility in Belgium, creating a springboard to crack the European market as the ASX’s second-largest biotechnology company behind CSL makes a global land grab.
Telix is only seven years old but increased its quarterly revenue almost 30-fold in the past 12 months as sales of Illuccix, its prostate cancer diagnostic agent, took off in the US.
Loading...
Hans van Leeuwen covers British and European politics, economics and business from London. He has worked as a reporter, editor and policy adviser in Sydney, Canberra, Hanoi and London. Connect with Hans on Twitter. Email Hans at hans.vanleeuwen@afr.com
